ROCKVILLE, MD / ACCESS Newswire / October 2, 2026 / American Gene Technologies (“AGT”), a clinical-stage biotech developing AGT103-T – the only program to demonstrate elimination of the HIV viral reservoir in humans – will present at the National Investment Banking Association (NIBA) 153rd Investment Conference on October 6-7, 2026.
AGT is raising $55 million to fund its Phase 2 trial of this one-time, gene-modified T-cell therapy targeting a functional cure for HIV in a $40 billion annual market. Backed by a successful Phase 1 trial, FDA Fast Track designation, 60+ patents.
kAmpv% H:== 36 2G2:=23=6 7@C @?6\@?\@?6 :?G6DE@C >66E:?8D @? ~4E@36C f] %@ D4965F=6 2 >66E:?8[ 4@?E24E sC6H !2=:?[ !C6D:56?E[ 2E k2 C6=lQ?@7@==@HQ 9C67lQ>2:=E@iH5A2=:?o2>6C:42?86?6]4@>QmH5A2=:?o2>6C:42?86?6]4@>k^2m @C G:D:E k2 C6=lQ?@7@==@HQ 9C67lQ9EEADi^^AC]C6A@CE^C8=JQm?:32?6E]@C8k^2m 7@C 56E2:=D]k^Am
kAm$~rti p>6C:42? v6?6 %649?@=@8:6Dk^Am
kAm’:6H E96 @C:8:?2=k^Am
k2 9C67lQ9EEADi^^HHH]2446DD?6HDH:C6]4@>^?6HDC@@>^6?^3:@E649?@=@8J^2>6C:42?\86?6\E649?@=@8:6D\E@\AC6D6?E\2E\E96\?:32\`dbC5\:?G6DE>6?E\4@?76C6?46\:?\7@CE\`ab_dceQmAC6DD C6=62D6k^2m
kAm@? prrt$$ }6HDH:C6k^Am
Copyright 2026 ACCESS Newswire. All Rights Reserved.